| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 2,922 | 856 | - | - |
| Cost of products and services-Service | 1,035 | 1,092 | - | - |
| Research and development | 12,377 | 11,488 | - | - |
| Total revenues | - | - | 1,341 | 66 |
| Selling, general and administrative | 23,991 | 16,133 | 12,359 | 9,836 |
| Impairment of goodwill | 0 | 3,907 | - | - |
| Research and development | - | - | 10,478 | 11,370 |
| Impairment of other noncurrent assets | 0 | 0 | - | - |
| Cost of products and services | - | - | 1,100 | 1,009 |
| Total operating expenses | 37,403 | 32,620 | 23,937 | 22,215 |
| Operating loss | -34,481 | -31,764 | -22,596 | -21,262 |
| Change in fair value of warrant liabilities | -111,502 | 4,460 | - | - |
| Other income, net | - | - | 7 | -2,985 |
| Interest expense | 902 | 0 | - | - |
| Interest income | 534 | 696 | 918 | 283 |
| Interest expense | - | - | 1 | 2 |
| Other (expense) income, net | 7 | -31 | - | - |
| Change in fair value of warrant liabilities | - | - | -32,481 | - |
| Total other expense, net | -111,863 | 5,125 | - | - |
| Total other (expense) income, net | - | - | -31,557 | -2,704 |
| Loss before income taxes | -146,344 | -26,639 | -54,153 | -23,966 |
| Income tax (expense) benefit | 0 | 3 | - | - |
| Income tax (expense) benefit | - | 3 | - | 12 |
| Net loss | -146,344 | -26,642 | -54,153 | -23,978 |
| Deemed dividend on preferred stock | 179,000 | - | - | - |
| Net loss attributable to common shareholders | -325,344 | - | - | - |
| Net loss per share, basic (in dollars per share) | -1.06 | -0.09 | -0.18 | -0.09 |
| Net loss per share, diluted (in dollars per share) | -1.06 | -0.09 | -0.18 | -0.09 |
| Weighted average shares outstanding, basic (in shares) | 307,170,490 | 296,434,726 | 293,879,653 | 275,881,170 |
| Weighted average shares outstanding, diluted (in shares) | 307,170,490 | 296,434,726 | 293,879,653 | 275,881,170 |
PRECIGEN, INC. (PGEN)
PRECIGEN, INC. (PGEN)